FDA Snubs Ozempic and Similar Drugs from Key Compounding List
Published Date: 5/1/2026
Notice
Summary
The FDA is updating a special list of important drug ingredients that compounding pharmacies can use to make medicines. They decided not to add three popular drugs—semaglutide, tirzepatide, and liraglutide—to this list right now. People and companies have until June 30, 2026, to share their thoughts, which could affect future drug availability and costs.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 2 costs, 1 mixed.
Three Drugs Not Added Now
The FDA proposes NOT to add semaglutide, tirzepatide, and liraglutide to the Section 503B Bulks List. That means outsourcing compounding facilities may not lawfully compound using those bulk drug substances unless the substance later appears on the 503B Bulks List or the drug product is on FDA's drug shortage list at the time of compounding.
What FDA Won't Count As 'Clinical Need'
When deciding whether a bulk drug substance belongs on the 503B Bulks List, FDA says it will not treat supply issues (such as backorders), convenience of administration, or the cost of a compounded product versus an FDA-approved product as a basis for 'clinical need.'
Public Comment Deadline Set
FDA is accepting electronic or written comments on this notice through June 30, 2026. Stakeholders must submit comments by 11:59 p.m. Eastern Time on June 30, 2026 for them to be considered.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-08551 — Florida Power and Light Company; St. Lucie Plant, Units 1 and 2; Subsequent License Renewal and Record of Decision
Florida Power and Light just got the green light to keep running its St. Lucie nuclear plant, Units 1 and 2, for even longer! This means the plant can keep providing power safely and reliably, helping Florida’s energy needs without interruption. The new licenses were officially issued on April 28, 2026, ensuring steady energy and supporting local jobs without extra costs to customers right now.
Next: 2026-08553 — Supply Chain Gaps and Entrepreneur Assistance
The SBA wants your ideas on how to fix supply chain problems in important industries and help entrepreneurs grow with better tech support. Small businesses and startups are the stars here, and your feedback by May 18, 2026, will shape new programs to boost innovation and keep the U.S. competitive. No money is offered for comments, but your voice could spark big changes!